Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 30;612(7939):301–309. doi: 10.1038/s41586-022-05448-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Springer Nature Limited 2022, corrected publication 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Extended Data Fig. 7 — A-B. Survival curves are drawn showing that IL6R p.Asp358Ala mutation carriers (green) are not an elevated risk of CVD incidence (y-axis) compared with non-carriers (blue) in either the first 50K individuals from UKB (A) or the full 450K cohort (B). C-D. In contrast, IL6R p.Asp358Ala mutation carriers are estimated to be at a reduced risk of CVD events (C) (HR = 0.60), but only in the first 50K samples from UKB (D). Models are adjusted for sex, LDL, HDL, pack years, smoking status, BMI, essential primary hypertension, type 2 diabetes mellitus, and 10 European specific genetic PCs. Hazard ratios (HR) were estimated using cox-proportional hazard modeling, with p-values uncorrected and derived from two-sided Wald tests.